venBio Partners L.P. - Q4 2018 holdings

$38.1 Million is the total value of venBio Partners L.P.'s 3 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 0.0% .

 Value Shares↓ Weighting
 Apellis Pharmaceuticals, Inc$23,611,000
-25.8%
1,790,1020.0%62.01%
+11.4%
VRNA  Verona Pharma PLCsponsored ads$8,444,000
-22.9%
875,0000.0%22.18%
+15.8%
MNLO  Menlo Therapeutics Inc.$6,022,000
-58.2%
1,461,5520.0%15.82%
-37.2%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Apellis Pharmaceuticals, Inc5Q4 201877.1%
Verona Pharma PLC5Q4 201822.2%
Menlo Therapeutics Inc.4Q4 201833.9%
Nabriva Therapeutics PLC3Q2 201812.6%

View venBio Partners L.P.'s complete holdings history.

Latest filings
TypeFiled
13F-HR2019-02-14
13F-HR2018-11-14
13F-HR2018-08-14
13F-HR2018-04-25
13F-HR2018-04-25

View venBio Partners L.P.'s complete filings history.

Compare quarters

Export venBio Partners L.P.'s holdings